In ALPINE, overall response rates were higher with Zanu versus Ib, including in patients with TP53 aberrant CLL (80.5% vs. 50.0%), see Table 1 [63]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.